Filing Details
- Accession Number:
- 0001140361-17-009668
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-02-28 16:37:00
- Reporting Period:
- 2017-02-24
- Filing Date:
- 2017-02-28
- Accepted Time:
- 2017-02-28 16:37:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1048477 | Biomarin Pharmaceutical Inc | BMRN | Pharmaceutical Preparations (2834) | 680397820 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1197355 | J Henry Fuchs | C/O Biomarin Pharmaceutical Inc. 770 Lindaro St. San Rafael CA 94901 | President, Worldwide R&D | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-02-24 | 14,564 | $0.00 | 128,442 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2017-02-24 | 15,000 | $26.49 | 143,442 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-02-24 | 15,000 | $87.99 | 128,442 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to buy Common Stock) | Disposition | 2017-02-24 | 15,000 | $0.00 | 15,000 | $26.49 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 20,225 | 2011-11-12 | 2021-05-11 | No | 4 | M | Direct |
Footnotes
- Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
- Represents the total number of RSUs earned pursuant to a calculation based on the level of the Issuer's total adjusted revenues for the fiscal year ended December 31, 2016, as certified by its audited financials, set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan.
- Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2017, 2018 and 2019, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain corporate events.
- Trade made pursuant to a 10b5-1 plan executed on May 12, 2016.
- All shares were sold at the same price.
- Reflects the number of stock options outstanding after the transaction from this specific stock option grant.
Billionaire Hedge Funds
